A randomized controlled trial of the efficacy and safety of varenicline for smoking cessation after acute coronary syndrome: Design and methods of the Evaluation of Varenicline in Smoking Cessation for Patients Post-Acute Coronary Syndrome trial

Citation metadata

From: American Heart Journal(Vol. 170, Issue 4)
Publisher: Elsevier B.V.
Document Type: Article
Length: 135 words

Document controls

Main content

Abstract :

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ahj.2015.07.010 Byline: Sarah B. Windle, Iqbal Bata, Mina Madan, Beth L. Abramson, Mark J. Eisenberg Abstract: Patients who continue to smoke after an acute coronary syndrome (ACS) have a significantly increased risk of reinfarction and death compared with those who quit. Varenicline is a first-line smoking cessation therapy with proven efficacy in the general population. However, its efficacy and safety immediately after an ACS are unknown. Article History: Received 25 March 2015; Accepted 11 July 2015 Article Note: (footnote) Randomized controlled trial no. NCT00794573., Funding source: EVITA is an investigator-initiated trial, which received funding and study drug/placebo from Pfizer Canada Inc (Kirkland, Quebec, Canada). Pfizer Canada Inc has no role in the design, conduct, analysis, interpretation of data, or reporting of the EVITA trial.

Source Citation

Source Citation   

Gale Document Number: GALE|A432690579